Dr. Steven Domsky, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
100 E Lancaster Ave, The Heart Pavillion, Mezzanine Level
Wynnewood, PA 19096
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 845
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Temple University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
PA license MD431531 -
Cardiovascular Disease Physician
PA license MD431531
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Main Line Hospital Lankenau Wynnewood, PA
- Paoli Hospital Paoli, PA
- Bryn Mawr Hospital Bryn Mawr, PA
- Riddle Memorial Hospital Media, PA
Medical groups
- Main Line Healthcare (1,184 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 845
- Services billed
- 3,343
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 633 | 371 |
| Established patient office or other outpatient visit, 30-39 minutes | 495 | 318 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 391 | 129 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 298 | 111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 242 | 229 |
| Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | 140 | 61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 117 | 117 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 91 | 74 |
| Established patient office or other outpatient visit, 40-54 minutes | 89 | 68 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 73 | 73 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Wynnewood, PA | 389 |
| Atorvastatin Calcium Other prescribers in Wynnewood, PA | 372 |
| Entresto (sacubitril/valsartan) Other prescribers in Wynnewood, PA | 298 |
| Carvedilol Other prescribers in Wynnewood, PA | 238 |
| Spironolactone Other prescribers in Wynnewood, PA | 231 |
| Furosemide Other prescribers in Wynnewood, PA | 213 |
| Torsemide Other prescribers in Wynnewood, PA | 188 |
| Eliquis (apixaban) Other prescribers in Wynnewood, PA | 188 |
| Vyndamax (tafamidis) | 160 |
| Rosuvastatin Calcium Other prescribers in Wynnewood, PA | 159 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 93 payments worth $40,159 in total to this clinician.
| Bridgebio Pharma, Inc. | $15,255 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $13,619 |
| E.r. Squibb & Sons, L.l.c. | $6,969 |
| Pfizer Inc. | $3,198 |
| Impulse Dynamics (USA) Inc. | $271 |
| Abiomed | $207 |
| United Therapeutics Corporation | $186 |
| Abbott Laboratories | $155 |
| Compensation for services other than consulting (speaking, faculty) | $35,604 |
|---|---|
| Food and Beverage | $2,575 |
| Travel and Lodging | $1,370 |
| Consulting Fee | $510 |
| Education | $98.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $5,040 |
| E.r. Squibb & Sons, L.l.c. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,080 |
| Pfizer Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $3,125 |
| Actelion Pharmaceuticals US, Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Actelion Pharmaceuticals US, Inc. Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Actelion Pharmaceuticals US, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| E.r. Squibb & Sons, L.l.c. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,083 |
| Bridgebio Pharma, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
| Bridgebio Pharma, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
| Bridgebio Pharma, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bridgebio Pharma, Inc. Dec 18, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Philadelphia, PA | $23.80 |
| Abiomed Dec 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $11.63 |
| Bridgebio Pharma, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
| Bridgebio Pharma, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $831 |
| Bridgebio Pharma, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
| Bridgebio Pharma, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $831 |
| Actelion Pharmaceuticals US, Inc. Nov 4, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to King of Prussia, PA | $13.30 |
| Actelion Pharmaceuticals US, Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Bridgebio Pharma, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
| Bridgebio Pharma, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
| Actelion Pharmaceuticals US, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Bridgebio Pharma, Inc. Oct 16, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Rehoboth Beach, DE · in-kind | $1,322 |
| Actelion Pharmaceuticals US, Inc. Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Bridgebio Pharma, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
| Bridgebio Pharma, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $831 |
| Pfizer Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $3,125 |
| Bridgebio Pharma, Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,662 |
| Bridgebio Pharma, Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $831 |
| Actelion Pharmaceuticals US, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $5,040 |
| E.r. Squibb & Sons, L.l.c. Apr 28, 2025 | Consulting Fee | $510 |
| Actelion Pharmaceuticals US, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $420 |
| Actelion Pharmaceuticals US, Inc. Apr 8, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $98.99 |
| E.r. Squibb & Sons, L.l.c. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,080 |
| E.r. Squibb & Sons, L.l.c. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,083 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $373,408 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserv…
Merck Sharp & Dohme LLC - A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.